ArticlePediatric pulmonology2026
Efficacy of High-Dose Versus Conventional-Dose Methylprednisolone in Reducing the Risk of Chronic Lung Disease in Chinese Children With Severe Mycoplasma pneumoniae Pneumonia: A Retrospective Study.
Article in Pediatric pulmonology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThis study aimed to compare the clinical efficacy of high-dose versus conventional-dose methylprednisolone therapy and the prevalence of chronic lung disease (CLD) at the 6-month follow-up in Chinese children with severe Mycoplasma pneumoniae pneumonia (SMPP).
methodsA retrospective cohort study was performed on 82 children with SMPP admitted from January 2018 to January 2024. Patients were categorized into high-dose and conventional-dose groups based on initial glucocorticoid dosage. Clinical data, laboratory tests, chest imaging, and bronchoscopy findings were reviewed to compare pulmonary conditions and therapeutic efficacy. The prevalence of CLD, oxygen saturation levels, and pulmonary function were assessed at the 6-month follow-up.
resultsThe main clinical features of SMPP included persistent high fever, cough, excessive inflammation (C-reactive protein, erythrocyte sedimentation rate, procalcitonin, interleukin-6, lactate dehydrogenase, serum ferritin, and D-Dimer), as well as severe pulmonary involvement, including consolidation, pleural effusion, and lung necrosis on computed tomography, and mucus plugging on bronchoscopy. Disease severity was comparable between groups, but the high-dose group exhibited a shorter fever duration (9.8 vs. 16.1 days), faster defervescence after corticosteroid treatment (1.0 vs. 7.0 days), and reduced hospitalization (13.4 vs. 18.4 days) (all p < 0.001). At the 6-month follow-up, the high-dose group had a significantly lower prevalence of CLD (28.2% vs. 85.4%) (p < 0.001), higher oxygen saturation levels (p = 0.033) and better pulmonary function (p < 0.001).
conclusionHigh-dose methylprednisolone therapy was more effective than conventional-dose treatment for SMPP patients. It was also associated with a lower prevalence of CLD, higher oxygen saturation levels, and better pulmonary function outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.